DOACs in pacemaker or defibrillator surgery 83 20. I. Ahmed, E. Gertner, W.B. Nelson, C.M. House, D.W.X. Zhu, Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation, J. Interv. Card Electrophysiol., 29 (3) (2010), pp. 203-207 21. J.E. Poole, M.J. Gleva, T. Mela, M.K. Chung, D.Z. Uslan, R. Borge, V. Gottipaty, T. Shinn, D. Dan, L.A. Feldman, H. Seide, S.A. Winston, J.J. Gallagher, J.J. Langberg, K. Mitchell, R. Holcomb, Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry, Circulation, 122 (16) (2010), pp. 1553-1561 22. M.S. Buiten, M..K. De bie, A.C. Van der heijden, J.I. Rotmans, M. Bootsma, J.H. Marc groeneveld, RON Wolterbeek, T.J. Rabelink, J.W. Jukema, M.J. Schalij, L. Van erven, L VANE. Chronic kidney disease and implantable cardioverter defibrillator related complications: 16 years of experience, J. Cardiovasc. Electrophysiol., 25 (9) (2014), pp. 998-1004 23. V. Essebag, J.S. Healey, J. Joza, P.B. Nery, E. Kalfon, T.L.L. Leiria, A. Verma, F. Ayala-Paredes, B. Coutu, G.L. Sumner, G. Becker, F. Philippon, J. Eikelboom, R.K. Sandhu, J. Sapp, R. Leather, D. Yung, B. Thibault, C.S. Simpson, K. Ahmad, S. Toal, M. Sturmer, K. Kavanagh, E. Crystal, G.A. Wells, A.D. Krahn, D.H. Birnie, Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2, Circ. Arrhythm. Electrophysiol., 12 (10) (2019) 24. C.-T. Tsai, J.-N. Liao, T.-F. Chao, Y.-J. Lin, S.-L. Chang, L.-W. Lo, Y.-F. Hu, F.-P. Chung, T.-C. Tuan, S.-A. Chen, Uninterrupted non-vitamin K antagonist oral anticoagulants during implantation of cardiac implantable electronic devices in patients with atrial fibrillation, J. Chin. Med. Assoc., 82 (4) (2019), pp. 256-259 25. D. Ricciardi, A. Creta, I. Colaiori, D. Scordino, L. Ragni, F. Picarelli, V. Calabrese, R. Providência, A. Ioannou, G. Di Sciascio, Interrupted versus uninterrupted novel oral anticoagulant peri-implantation of cardiac device: A single-center randomized prospective pilot trial, Pacing. Clin. Electrophysiol., 41 (11) (2018), pp. 1476-1480 26. L.A. de Jong, M. Koops, J.J. Gout-Zwart, J. Brouwers, et al., Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference, Neth. J. Med., 76 (2018), pp. 426-430 27. V. Ten Cate, H. Ten Cate, F.W. Verheugt, The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with nonvalvular atrial fibrillation in the Netherlands, Neth. Heart J., 24 (2016), pp. 574-580 28. P. Kirchhof, B.F. Blank, M. Calvert, A.J. Camm, G. Chlouverakis, H.-C. Diener, A. Goette, A. Huening, G.Y.H. Lip, E. Simantirakis, P. Vardas, Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial, Am. Heart J., 190 (2017), pp. 12-18 29. R.D. Lopes, M. Alings, S.J. Connolly, H. Beresh, C.B. Granger, J.B. Mazuecos, G. Boriani, J.C. Nielsen, D. Conen, S.H. Hohnloser, G.H. Mairesse, P. Mabo, A.J. Camm, J.S. Healey, Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial, Am. Heart J., 189 (2017), pp. 137-145 5
RkJQdWJsaXNoZXIy MTk4NDMw